Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

S&P Hits Record High as Bulls Continue Stampede; Apple Hits $2T Valuation

Published 2020-08-19, 12:40 p/m
© Reuters.
US500
-
DJI
-
MSFT
-
GILD
-
GOOGL
-
AAPL
-
AMZN
-
TGT
-
LOW
-
IXIC
-
BMRN
-
META
-
GOOG
-

By Yasin Ebrahim

Investing.com – The S&P 500 continued to flirt with record highs, underpinned by better-than-expected quarterly results from retailers and a boost from Apple as the tech giant’s valuation reached an unprecedented $2 trillion.

The S&P 500 rose 0.15% to 3,395, surging above its previous all-time intraday of 3,393.52 earlier in the session. The Dow Jones Industrial Average rose 0.15%, or 41 points. while the Nasdaq Composite gained 0.25%.

The last wave of quarterly results trickling through continued to show that retailers like Target (NYSE:TGT) and Lowe’s Companies Inc (NYSE:LOW) benefited from a pandemic-led boost in sales. 

Target jumped 12% reported that second-quarter results beat on both the top and bottom lines with same-store sales growing 24.3% for the quarter, above consensus estimates of 7.6%. 

Lowe’s shares gained 0.3% as the home-improvement retailer delivered earnings and revenue that topped expectations. 

Industrials and financials, sectors that tend to outperform as the economy strengthens, also led the charge higher in the broader market as investors continue to bet on a faster economic recovery. 

In tech, meanwhile, Apple (NASDAQ:AAPL) became the first company to reach a $2 trillion valuation after gaining 1% to trade above $467.73.

The other Fab 5 stocks, with the exception of Amazon.com (NASDAQ:AMZN), were higher. Microsoft (NASDAQ:MSFT), Facebook (NASDAQ:FB) and Alphabet (NASDAQ:GOOGL) traded above the flatline. 

Energy, however, struggled to join in the move higher, pressured by decline in oil prices as crude inventories declined by 1.6 million barrels last week, short of forecasts for a draw of 2.67 million barrels. 

In other news, Gilead Sciences (NASDAQ:GILD) was dealt a blow after the U.S. Food and Drug Administration rejected the company’s experimental treatment for moderately to severely active rheumatoid arthritis. Its shares fell 4%.

BioMarin Pharmaceutical (NASDAQ:BMRN), meanwhile, slumped 36% after the FDA Food and Drug Administration rejected its hemophilia drug, citing the need for further proof.

Investor attention will shift toward monetary policy as the minutes of the Federal Reserve July meeting are set to be released later. 

The minutes will be parsed for clues on the bank's widely expected plans to roll out average inflation targeting, in which inflation would be allowed to overshoot the Fed’s 2% target.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.